Faegre Drinker Represents Teva Pharmaceutical in its Agreement to Acquire Emalex Biosciences

Faegre Drinker advised leading biopharmaceutical company Teva Pharmaceutical in its agreement to acquire Emalex Biosciences, expanding Teva’s innovative medicines pipeline and supporting their growth.

Emalex Biosciences was created to develop new treatments for central nervous system disorders and other conditions with limited treatment options. Emalex’s lead asset, ecopipam, is a first-in-class investigational asset for pediatric Tourette syndrome with FDA Orphan Drug and Fast Track designations.

Upon closing, Teva will pay $700 million, and Emalex’s shareholders will be eligible to receive up to $200 million based on future commercial milestones as well as royalties on global net sales of ecopipam, subject to regulatory approval. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals.

The Faegre Drinker team was led by corporate partners Jonathan Nygren and Eli Isaacs and included corporate partners Jonathan Zimmerman and Matthew Levy, corporate associates Brian Kollatz, Sabra Drummond, Molly Madden, Yoshi Haynie, Caleb Hain, Peggy Morgan and Mihajlo Gasic, intellectual property partner Craig Komanecki and associate Joseph Decker, FDA regulatory partner Barrett Tenbarge and associate Carly Helman, antitrust partner Heather Burke, counsel Jonathan Todt and associate Jose Lopez, tax partner Lisa Pugh, labor and employment partner Nicole Truso and associate Allie Kruse, employee benefits partner Page Fleeger and associates Inés Sosa and Kasia Crain and privacy partner Doriann Cain. 

Read Teva’s press release for more information on the deal.